Madrigal Pharmaceuticals Shares Still Undervalued Amid Long-Term Growth Potential, UBS Says

MT Newswires Live

02-28

Madrigal Pharmaceuticals' (MDGL) shares remain undervalued given the company's long-term potential opportunity from its Rezdiffra MASH business, UBS said Thursday in a note.

The firm's upbeat outlook comes a day after the company said patients with metabolic dysfunction-associated steatohepatitis, or MASH, treated with its Rezdiffra drug showed "marked reductions" in liver stiffness.

UBS said the Rezdiffra launch is expected to accelerate significantly in 2025, supported by robust demand and manageable competition.

The firm sees potential for outperformance relative to consensus estimates for the the company this year as "strong MASH launches" should continue.

UBS reiterates its buy rating on the stock with a $441 price target.

Price: 349.03, Change: -6.85, Percent Change: -1.92

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2514333530"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514333530\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2514333530?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-28 01:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514333530","market":"hk","top_or_hot":-1,"title":"Madrigal Pharmaceuticals Shares Still Undervalued Amid Long-Term Growth Potential, UBS Says","media":"MT Newswires Live","content":"<html><body><p> Madrigal Pharmaceuticals' (MDGL) shares remain undervalued given the company's long-term potential opportunity from its Rezdiffra MASH business, UBS said Thursday in a note.</p><p>The firm's upbeat outlook comes a day after the company said patients with metabolic dysfunction-associated steatohepatitis, or MASH, treated with its Rezdiffra drug showed \"marked reductions\" in liver stiffness.</p><p>UBS said the Rezdiffra launch is expected to accelerate significantly in 2025, supported by robust demand and manageable competition.</p><p>The firm sees potential for outperformance relative to consensus estimates for the the company this year as \"strong MASH launches\" should continue.</p><p>UBS reiterates its buy rating on the stock with a $441 price target.</p><p>Price: 349.03, Change: -6.85, Percent Change: -1.92</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Madrigal Pharmaceuticals Shares Still Undervalued Amid Long-Term Growth Potential, UBS Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMadrigal Pharmaceuticals Shares Still Undervalued Amid Long-Term Growth Potential, UBS Says\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-02-28 01:36</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Madrigal Pharmaceuticals' (MDGL) shares remain undervalued given the company's long-term potential opportunity from its Rezdiffra MASH business, UBS said Thursday in a note.</p><p>The firm's upbeat outlook comes a day after the company said patients with metabolic dysfunction-associated steatohepatitis, or MASH, treated with its Rezdiffra drug showed \"marked reductions\" in liver stiffness.</p><p>UBS said the Rezdiffra launch is expected to accelerate significantly in 2025, supported by robust demand and manageable competition.</p><p>The firm sees potential for outperformance relative to consensus estimates for the the company this year as \"strong MASH launches\" should continue.</p><p>UBS reiterates its buy rating on the stock with a $441 price target.</p><p>Price: 349.03, Change: -6.85, Percent Change: -1.92</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDGL","symbol_name":"Madrigal Pharmaceuticals, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2514333530","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514333530","pubTimestamp":1740677764,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Madrigal Pharmaceuticals'  shares remain undervalued given the company's long-term potential opportunity from its Rezdiffra MASH business, UBS said Thursday in a note.The firm's upbeat outlook comes a day after the company said patients with metabolic dysfunction-associated steatohepatitis, or MASH, treated with its Rezdiffra drug showed \"marked reductions\" in liver stiffness.UBS said the Rezdiffra launch is expected to accelerate significantly in 2025, supported by robust demand and manageable competition.The firm sees potential for outperformance relative to consensus estimates for the the company this year as \"strong MASH launches\" should continue.UBS reiterates its buy rating on the stock with a $441 price target.Price: 349.03, Change: -6.85, Percent Change: -1.92","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MDGL":"Madrigal Pharmaceuticals, Inc.","BK4139":"生物科技","BK4585":"ETF&股票定投概念","BK4588":"碎股"},"translate_title":"瑞银表示，Madrigal Pharmaceuticals股价在长期增长潜力中仍被低估","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDGL":1},"content_text":"Madrigal Pharmaceuticals' (MDGL) shares remain undervalued given the company's long-term potential opportunity from its Rezdiffra MASH business, UBS said Thursday in a note.The firm's upbeat outlook comes a day after the company said patients with metabolic dysfunction-associated steatohepatitis, or MASH, treated with its Rezdiffra drug showed \"marked reductions\" in liver stiffness.UBS said the Rezdiffra launch is expected to accelerate significantly in 2025, supported by robust demand and manageable competition.The firm sees potential for outperformance relative to consensus estimates for the the company this year as \"strong MASH launches\" should continue.UBS reiterates its buy rating on the stock with a $441 price target.Price: 349.03, Change: -6.85, Percent Change: -1.92","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}